Fast Track Designation is given to drugs that are intended to treat serious conditions and or fill an unmet medical need.

The fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious ...

Those with ALS have an average survival of around two to five years from diagnosis, with most ALS patients dying from ...

The pharma companys Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company, has announced that the USFDA has granted ‘Fast Track ...

After a record FY25, the drugmaker sees new growth engines in biologics, vaccines, and devices powering expansion in FY26.

The ‘Easiest Exam’ campaign promotes early detection of breast cancer, amassing over 164 million impressions and encouraging ...

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

Devan Choksey is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1069 in its research report dated May 26, 2025.

Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It ...

Results: Net profit for the quarter fell 1% from the year-ago period to ₹1,171 crore. The company reported a one-time loss of ...